News

The study results include chronic lymphocytic leukemia (CLL), multiple myeloma (MM), indolent NHL and MCL lymphoid malignancies. Of the 43 abstracts, five include oral presentations, according to the

Gengos has served several companies and gained experience in areas such as corporate strategy, business development and transactions. ImmunoCellular founder and chief scientific officer John Yu said, "ImmunoCellular’s

The research will leverage the MolecularBreeding technology platform that offers new approach in developing vaccines targeting different HIV-1 strains. Altravax chief scientific officer Dr. Robert Whalen said the

Cancer Panels, which are available through Illumina and LifeTechnologies platforms, have the ability to screen and detect cancer causing genetic mutations from small amount of DNA. Cancer Panels

The trial will assess Erwinaze asparaginase-based therapy that is believed to play a vital role for ALL patients not left with any other treatment options and is expected

Under the deal, biOasis will conduct certain experiments using its technology, as it relates to the delivery of therapeutic compounds owned by UCB for CNS disorders. biOasis Technologie

As part of the expansion, the companies have renewed collaboration in Brazil and Argentina and also extended the partnership to Australia where Galderma will have exclusive promotion and

The double-blind, multicenter trial led by AVEO is designed to assess the efficacy profile of tivozanib combination therapy with paclitaxel against placebo combination therapy with paclitaxel in advanced

The contract research organization will leverage the platform that is compliant with 21 CFR Part 11 to simplify study management and reduce redundancies accompanying paper-based studies. WCT chief